Evidence map›Paper›PMID 42460008›Full record

ArticleFrontiers in pharmacology2026

Marina Ionela Nedea, Serena-Ștefania Velicu, Ioana Cristina Marinaş, Mihaela Buleandră, Andreea Letiția Arsene, Bruno Ștefan Velescu, Mariana Carmen Chifiriuc, Irina Gheorghe-Barbu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marina Ionela NedeaFaculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Serena-Ștefania VelicuFaculty of Biology, University of Bucharest, Bucharest, Romania.
Ioana Cristina MarinaşThe Research Institute of the University of Bucharest (ICUB), Bucharest, Romania.
Mihaela BuleandrăFaculty of Chemistry, University of Bucharest, Bucharest, Romania.
Andreea Letiția ArseneFaculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Bruno Ștefan VelescuFaculty of Pharmacy, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Mariana Carmen ChifiriucFaculty of Biology, University of Bucharest, Bucharest, Romania.
Irina Gheorghe-BarbuFaculty of Biology, University of Bucharest, Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Antifungal resistance in Methods: The chemical composition of the EO was analyzed by gas chromatography-mass spectrometry. Antifungal activity was assessed by broth microdilution (minimum inhibitory concentration determination), while anti-adherence effects were evaluated using the microtitration with crystal violet. The fractional inhibitory concentration index and response surface approach were used to study synergistic interactions. The Results: The most significant phenylpropanoid components of the EO were (E)-cinnamaldehyde and eugenol. It demonstrated high antifungal activity and significantly decreased adherence to the inert substratum. The tested EO exhibited pharmacological synergy in combination with fluconazole, especially against fluconazole-resistant Conclusion:

Indexed as

antifungalanti-virulencecombination therapyin vivo modelmultidrug-resistant Candida strainssynergistic effects

Identifiers

PMID42460008
PMCPMC13369618

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.